Diagnostics / pathology

Breast Cancer Immunotherapy Has a New Problem: Who Gets the Second Checkpoint?

Alzheimer’s Diagnosis Gets Another Gate

ctDNA Is Becoming a Surveillance Policy, Not Just a Test

AI Wants to Choose Pancreatic Chemo

Prevention Is Now Alzheimer’s Hardest Trial

ctDNA Is Becoming the New Argument Over Chemotherapy

Migraine Still Refuses a Simple Blood Test

Tissue-Agnostic Medicine Has a New Proof Point

A Blood Test Can See Risk. Policy Cannot Yet Hold It.
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
